{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["PI3K/Akt/mTOR", "STAT3", "isodon", "lasiokaurin", "triple-negative breast cancer"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "38067432", "DateCompleted": {"Year": "2023", "Month": "12", "Day": "16"}, "DateRevised": {"Year": "2023", "Month": "12", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "11", "Day": "22"}], "Language": ["eng"], "ELocationID": ["7701", "10.3390/molecules28237701"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "28", "Issue": "23", "PubDate": {"Year": "2023", "Month": "Nov", "Day": "22"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "In Vitro and In Vivo Anti-Cancer Activity of Lasiokaurin in a Triple-Negative Breast Cancer Model.", "Abstract": {"AbstractText": ["Due to its intricate heterogeneity, high invasiveness, and poor prognosis, triple-negative breast cancer (TNBC) stands out as the most formidable subtype of breast cancer. At present, chemotherapy remains the prevailing treatment modality for TNBC, primarily due to its lack of estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth receptor 2 (HER2). However, clinical chemotherapy for TNBC is marked by its limited efficacy and a pronounced incidence of adverse effects. Consequently, there is a pressing need for novel drugs to treat TNBC. Given the rich repository of diverse natural compounds in traditional Chinese medicine, identifying potential anti-TNBC agents is a viable strategy. This study investigated lasiokaurin (LAS), a natural diterpenoid abundantly present in Isodon plants, revealing its significant anti-TNBC activity both in vitro and in vivo. Notably, LAS treatment induced cell cycle arrest, apoptosis, and DNA damage in TNBC cells, while concurrently inhibiting cell metastasis. In addition, LAS effectively inhibited the activation of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway and signal transducer and activator of transcription 3 (STAT3), thus establishing its potential for multitarget therapy against TNBC. Furthermore, LAS demonstrated its ability to reduce tumor growth in a xenograft mouse model without exerting detrimental effects on the body weight or vital organs, confirming its safe applicability for TNBC treatment. Overall, this study shows that LAS is a potent candidate for treating TNBC."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China."}], "LastName": "Lin", "ForeName": "Jinrong", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Third-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, Medical College, China Three Gorges University, Yichang 443002, China."}], "LastName": "Qu", "ForeName": "Zhao", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China."}], "LastName": "Pu", "ForeName": "Huanhuan", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chongqing Academy of Chinese Materia Medica, Chongqing 400065, China."}], "LastName": "Shen", "ForeName": "Li-Sha", "Initials": "LS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Animal Science and Technology, Xinyang Agricultural and Forestry University, Xinyang 464000, China."}], "LastName": "Yi", "ForeName": "Xianguo", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Chinese Medicine and Molecular Pharmacology (Incubation), The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen 518057, China."}], "LastName": "Lin", "ForeName": "Yu-Shan", "Initials": "YS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong 999077, China."}], "LastName": "Gong", "ForeName": "Rui-Hong", "Initials": "RH"}, {"Identifier": ["0000-0002-3671-5257"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Chinese Medicine and Molecular Pharmacology (Incubation), The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen 518057, China."}, {"Identifier": [], "Affiliation": "Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong 999077, China."}, {"Identifier": [], "Affiliation": "Research Centre for Chinese Medicine Innovation, The Hong Kong Polytechnic University, Hung Hom, Hong Kong 999077, China."}], "LastName": "Chen", "ForeName": "Guo-Qing", "Initials": "GQ"}, {"Identifier": ["0000-0003-1539-9192"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Chinese Medicine and Molecular Pharmacology (Incubation), The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen 518057, China."}, {"Identifier": [], "Affiliation": "Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong 999077, China."}, {"Identifier": [], "Affiliation": "Research Centre for Chinese Medicine Innovation, The Hong Kong Polytechnic University, Hung Hom, Hong Kong 999077, China."}], "LastName": "Chen", "ForeName": "Sibao", "Initials": "S"}], "GrantList": [{"GrantID": "E-ABCT-BBBB-3", "Agency": "the Research Centre for Chinese Medicine Innovation of The Hong Kong Polytechnic Univer-sity", "Country": ""}, {"GrantID": "P0036741", "Agency": "The Hong Kong Polytechnic University Start-up Fund", "Country": ""}, {"GrantID": "P0038596", "Agency": "The Hong Kong Polytechnic University Start-up Fund", "Country": ""}, {"GrantID": "JA21026", "Agency": "Chongqing Science and Technology Commission", "Country": ""}, {"GrantID": "JCYJ20220531090802006", "Agency": "Shenzhen Science and Technology Innovation Commission", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "28957-08-6", "NameOfSubstance": "lasiokaurin"}, {"RegistryNumber": "EC 2.7.1.-", "NameOfSubstance": "Phosphatidylinositol 3-Kinases"}, {"RegistryNumber": "0", "NameOfSubstance": "Diterpenes"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": ["pathology"], "DescriptorName": "Triple Negative Breast Neoplasms"}, {"QualifierName": [], "DescriptorName": "Phosphatidylinositol 3-Kinases"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Diterpenes"}, {"QualifierName": [], "DescriptorName": "Apoptosis"}, {"QualifierName": [], "DescriptorName": "Mammals"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209\u2013249. doi: 10.3322/caac.21660.", "ArticleIdList": ["10.3322/caac.21660", "33538338"]}, {"Citation": "Garrido-Castro A.C., Lin N.U., Polyak K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019;9:176\u2013198. doi: 10.1158/2159-8290.CD-18-1177.", "ArticleIdList": ["10.1158/2159-8290.CD-18-1177", "PMC6387871", "30679171"]}, {"Citation": "Lee K.L., Kuo Y.C., Ho Y.S., Huang Y.H. Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness. Cancers. 2019;11:1334. doi: 10.3390/cancers11091334.", "ArticleIdList": ["10.3390/cancers11091334", "PMC6769912", "31505803"]}, {"Citation": "Bianchini G., Balko J.M., Mayer I.A., Sanders M.E., Gianni L. Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 2016;13:674\u2013690. doi: 10.1038/nrclinonc.2016.66.", "ArticleIdList": ["10.1038/nrclinonc.2016.66", "PMC5461122", "27184417"]}, {"Citation": "Shastry M., Yardley D.A. Updates in the treatment of basal/triple-negative breast cancer. Curr. Opin. Obstet. Gynecol. 2013;25:40\u201348. doi: 10.1097/GCO.0b013e32835c1633.", "ArticleIdList": ["10.1097/GCO.0b013e32835c1633", "23222093"]}, {"Citation": "Loibl S., Poortmans P., Morrow M., Denkert C., Curigliano G. Breast cancer. Lancet. 2021;397:1750\u20131769. doi: 10.1016/S0140-6736(20)32381-3.", "ArticleIdList": ["10.1016/S0140-6736(20)32381-3", "33812473"]}, {"Citation": "Shi C., Yang E.J., Tao S., Ren G., Mou P.K., Shim J.S. Natural products targeting cancer cell dependency. J. Antibiot. 2021;74:677\u2013686. doi: 10.1038/s41429-021-00438-x.", "ArticleIdList": ["10.1038/s41429-021-00438-x", "34163025"]}, {"Citation": "Gairola K., Gururani S., Bahuguna A., Garia V., Pujari R., Dubey S.K. Natural products targeting cancer stem cells: Implications for cancer chemoprevention and therapeutics. J. Food Biochem. 2021;45:e13772. doi: 10.1111/jfbc.13772.", "ArticleIdList": ["10.1111/jfbc.13772", "34028051"]}, {"Citation": "Chen H., Yang J., Yang Y., Zhang J., Xu Y., Lu X. The Natural Products and Extracts: Anti-Triple-Negative Breast Cancer in Vitro. Chem. Biodivers. 2021;18:e2001047. doi: 10.1002/cbdv.202001047.", "ArticleIdList": ["10.1002/cbdv.202001047", "34000082"]}, {"Citation": "Yap K.M., Sekar M., Seow L.J., Gan S.H., Bonam S.R., Mat Rani N.N.I., Lum P.T., Subramaniyan V., Wu Y.S., Fuloria N.K., et al. Mangifera indica (Mango): A Promising Medicinal Plant for Breast Cancer Therapy and Understanding Its Potential Mechanisms of Action. Breast Cancer. 2021;13:471\u2013503. doi: 10.2147/BCTT.S316667.", "ArticleIdList": ["10.2147/BCTT.S316667", "PMC8448164", "34548817"]}, {"Citation": "Yap K.M., Sekar M., Wu Y.S., Gan S.H., Rani N., Seow L.J., Subramaniyan V., Fuloria N.K., Fuloria S., Lum P.T. Hesperidin and its aglycone hesperetin in breast cancer therapy: A review of recent developments and future prospects. Saudi J. Biol. Sci. 2021;28:6730\u20136747. doi: 10.1016/j.sjbs.2021.07.046.", "ArticleIdList": ["10.1016/j.sjbs.2021.07.046", "PMC8626310", "34866972"]}, {"Citation": "Harley R.M., Atkins S., Budantsev A.L., Cantino P.D., Conn B.J., Grayer R., Harley M.M., de Kok R., Krestovskaja T., Morales R., et al. Labiatae. In: Kadereit J.W., editor. Flowering Plants Dicotyledons: Lamiales (Except Acanthaceae Including Avicenniaceae) Springer; Berlin/Heidelberg, Germany: 2004. pp. 167\u2013275."}, {"Citation": "Sun H.D., Huang S.X., Han Q.B. Diterpenoids from Isodon species and their biological activities. Nat. Prod. Rep. 2006;23:673\u2013698. doi: 10.1039/b604174d.", "ArticleIdList": ["10.1039/b604174d", "17003905"]}, {"Citation": "Liu M., Wang W.G., Sun H.D., Pu J.X. Diterpenoids from Isodon species: An update. Nat. Prod. Rep. 2017;34:1090\u20131140. doi: 10.1039/C7NP00027H.", "ArticleIdList": ["10.1039/C7NP00027H", "28758169"]}, {"Citation": "Li X., Zhang C.T., Ma W., Xie X., Huang Q. Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity. Front. Pharmacol. 2021;12:645824. doi: 10.3389/fphar.2021.645824.", "ArticleIdList": ["10.3389/fphar.2021.645824", "PMC8289702", "34295243"]}, {"Citation": "Guo J., Chen T., Ma Z., Qiao C., Yuan F., Guo X., Liu J., Shen Y., Yu L., Xiang A. Oridonin inhibits 4T1 tumor growth by suppressing Treg differentiation via TGF-beta receptor. Int. Immunopharmacol. 2020;88:106831. doi: 10.1016/j.intimp.2020.106831.", "ArticleIdList": ["10.1016/j.intimp.2020.106831", "32853925"]}, {"Citation": "Sun B., Wang G., Liu H., Liu P., Twal W.O., Cheung H., Carroll S.L., Ethier S.P., Mevers E.E., Clardy J., et al. Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget. 2018;9:23878\u201323889. doi: 10.18632/oncotarget.24378.", "ArticleIdList": ["10.18632/oncotarget.24378", "PMC5963618", "29844859"]}, {"Citation": "Li C., Wang Q., Shen S., Wei X., Li G. Oridonin inhibits VEGF-A-associated angiogenesis and epithelial-mesenchymal transition of breast cancer in vitro and in vivo. Oncol. Lett. 2018;16:2289\u20132298. doi: 10.3892/ol.2018.8943.", "ArticleIdList": ["10.3892/ol.2018.8943", "PMC6036431", "30008931"]}, {"Citation": "Bu H.Q., Shen F., Cui J. The inhibitory effect of oridonin on colon cancer was mediated by deactivation of TGF-beta1/Smads-PAI-1 signaling pathway in vitro and vivo. OncoTargets Ther. 2019;12:7467\u20137476. doi: 10.2147/OTT.S220401.", "ArticleIdList": ["10.2147/OTT.S220401", "PMC6752205", "31686852"]}, {"Citation": "Zhou J., Li Y., Shi X., Hao S., Zhang F., Guo Z., Gao Y., Guo H., Liu L. Oridonin inhibits tumor angiogenesis and induces vessel normalization in experimental colon cancer. J. Cancer. 2021;12:3257\u20133264. doi: 10.7150/jca.55929.", "ArticleIdList": ["10.7150/jca.55929", "PMC8100792", "33976735"]}, {"Citation": "Xu L., Bi Y., Xu Y., Zhang Z., Xu W., Zhang S., Chen J. Oridonin inhibits the migration and epithelial-to-mesenchymal transition of small cell lung cancer cells by suppressing FAK-ERK1/2 signalling pathway. J. Cell. Mol. Med. 2020;24:4480\u20134493. doi: 10.1111/jcmm.15106.", "ArticleIdList": ["10.1111/jcmm.15106", "PMC7176879", "32168416"]}, {"Citation": "Liu W., Huang G., Yang Y., Gao R., Zhang S., Kou B. Oridonin inhibits epithelial-mesenchymal transition of human nasopharyngeal carcinoma cells by negatively regulating AKT/STAT3 signaling pathway. Int. J. Med. Sci. 2021;18:81\u201387. doi: 10.7150/ijms.48552.", "ArticleIdList": ["10.7150/ijms.48552", "PMC7738957", "33390776"]}, {"Citation": "Yang J., Ren X., Zhang L., Li Y., Cheng B., Xia J. Oridonin inhibits oral cancer growth and PI3K/Akt signaling pathway. Biomed. Pharmacother. 2018;100:226\u2013232. doi: 10.1016/j.biopha.2018.02.011.", "ArticleIdList": ["10.1016/j.biopha.2018.02.011", "29432993"]}, {"Citation": "Liu Q.Q., Chen K., Ye Q., Jiang X.H., Sun Y.W. Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/beta-catenin signaling pathway. Cancer Cell Int. 2016;16:57. doi: 10.1186/s12935-016-0336-z.", "ArticleIdList": ["10.1186/s12935-016-0336-z", "PMC4957915", "27453691"]}, {"Citation": "Che X., Zhan J., Zhao F., Zhong Z., Chen M., Han R., Wang Y. Oridonin Promotes Apoptosis and Restrains the Viability and Migration of Bladder Cancer by Impeding TRPM7 Expression via the ERK and AKT Signaling Pathways. Biomed. Res. Int. 2021;2021:4340950. doi: 10.1155/2021/4340950.", "ArticleIdList": ["10.1155/2021/4340950", "PMC8275389", "34285910"]}, {"Citation": "Zhu H.Q., Zhang C., Guo Z.Y., Yang J.M., Guo J.H., Chen C., Yao Q.H., Liu F., Zhang Q.W., Gao F.H. Oridonin induces Mdm2-p60 to promote p53-mediated apoptosis and cell cycle arrest in neuroblastoma. Cancer Med. 2019;8:5313\u20135326. doi: 10.1002/cam4.2393.", "ArticleIdList": ["10.1002/cam4.2393", "PMC6718599", "31339234"]}, {"Citation": "Li D.H., Hu P., Xu S.T., Fang C.Y., Tang S., Wang X.Y., Sun X.Y., Li H., Xu Y., Gu X.K., et al. Lasiokaurin derivatives: Synthesis, antimicrobial and antitumor biological evaluation, and apoptosis-inducing effects. Arch. Pharm. Res. 2017;40:796\u2013806. doi: 10.1007/s12272-016-0867-9.", "ArticleIdList": ["10.1007/s12272-016-0867-9", "28110416"]}, {"Citation": "Fujita E., Nagao Y., Node M., Kaneko K., Nakazawa S., Kuroda H. Antitumor activity of the Isodon diterpenoids: Structural requirements for the activity. Experientia. 1976;32:203\u2013206. doi: 10.1007/BF01937766.", "ArticleIdList": ["10.1007/BF01937766", "1269612"]}, {"Citation": "Nik Nabil W.N., Xi Z., Liu M., Li Y., Yao M., Liu T., Dong Q., Xu H. Advances in therapeutic agents targeting quiescent cancer cells. Acta Mater. Medica. 2022;1:56\u201371. doi: 10.15212/AMM-2021-0005.", "ArticleIdList": ["10.15212/AMM-2021-0005"]}, {"Citation": "Gong R.H., Yang D.J., Kwan H.Y., Lyu A.P., Chen G.Q., Bian Z.X. Cell death mechanisms induced by synergistic effects of halofuginone and artemisinin in colorectal cancer cells. Int. J. Med. Sci. 2022;19:175\u2013185. doi: 10.7150/ijms.66737.", "ArticleIdList": ["10.7150/ijms.66737", "PMC8692125", "34975311"]}, {"Citation": "Kim C., Kim B. Anti-Cancer Natural Products and Their Bioactive Compounds Inducing ER Stress-Mediated Apoptosis: A Review. Nutrients. 2018;10:1021. doi: 10.3390/nu10081021.", "ArticleIdList": ["10.3390/nu10081021", "PMC6115829", "30081573"]}, {"Citation": "Yap T.A., Plummer R., Azad N.S., Helleday T. The DNA Damaging Revolution: PARP Inhibitors and Beyond. Am. Soc. Clin. Oncol. Educ. Book. 2019;39:185\u2013195. doi: 10.1200/EDBK_238473.", "ArticleIdList": ["10.1200/EDBK_238473", "31099635"]}, {"Citation": "Yin L., Duan J.J., Bian X.W., Yu S.C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:61. doi: 10.1186/s13058-020-01296-5.", "ArticleIdList": ["10.1186/s13058-020-01296-5", "PMC7285581", "32517735"]}, {"Citation": "Zeichner S.B., Terawaki H., Gogineni K. A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. Breast Cancer. 2016;10:25\u201336. doi: 10.4137/BCBCR.S32783.", "ArticleIdList": ["10.4137/BCBCR.S32783", "PMC4807882", "27042088"]}, {"Citation": "Costa R.L.B., Han H.S., Gradishar W.J. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: A review. Breast Cancer Res. Treat. 2018;169:397\u2013406. doi: 10.1007/s10549-018-4697-y.", "ArticleIdList": ["10.1007/s10549-018-4697-y", "29417298"]}, {"Citation": "Xu F., Na L., Li Y., Chen L. Retraction Note to: Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours. Cell Biosci. 2021;11:157. doi: 10.1186/s13578-021-00667-5.", "ArticleIdList": ["10.1186/s13578-021-00667-5", "PMC8348868", "34362455"]}, {"Citation": "Khan M.A., Jain V.K., Rizwanullah M., Ahmad J., Jain K. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: A review on drug discovery and future challenges. Drug Discov. Today. 2019;24:2181\u20132191. doi: 10.1016/j.drudis.2019.09.001.", "ArticleIdList": ["10.1016/j.drudis.2019.09.001", "31520748"]}, {"Citation": "Sarbassov D.D., Ali S.M., Sabatini D.M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 2005;17:596\u2013603. doi: 10.1016/j.ceb.2005.09.009.", "ArticleIdList": ["10.1016/j.ceb.2005.09.009", "16226444"]}, {"Citation": "Jhanwar-Uniyal M., Wainwright J.V., Mohan A.L., Tobias M.E., Murali R., Gandhi C.D., Schmidt M.H. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. Adv. Biol. Regul. 2019;72:51\u201362. doi: 10.1016/j.jbior.2019.03.003.", "ArticleIdList": ["10.1016/j.jbior.2019.03.003", "31010692"]}, {"Citation": "Qin J.J., Yan L., Zhang J., Zhang W.D. STAT3 as a potential therapeutic target in triple negative breast cancer: A systematic review. J. Exp. Clin. Cancer Res. 2019;38:195. doi: 10.1186/s13046-019-1206-z.", "ArticleIdList": ["10.1186/s13046-019-1206-z", "PMC6518732", "31088482"]}, {"Citation": "Siersbaek R., Scabia V., Nagarajan S., Chernukhin I., Papachristou E.K., Broome R., Johnston S.J., Joosten S.E.P., Green A.R., Kumar S., et al. IL6/STAT3 Signaling Hijacks Estrogen Receptor alpha Enhancers to Drive Breast Cancer Metastasis. Cancer Cell. 2020;38:412\u2013423.e9. doi: 10.1016/j.ccell.2020.06.007.", "ArticleIdList": ["10.1016/j.ccell.2020.06.007", "PMC7116707", "32679107"]}, {"Citation": "Williams K., Sobol R.W. Mutation research/fundamental and molecular mechanisms of mutagenesis: Special issue: DNA repair and genetic instability. Mutat. Res. 2013;743:1\u20133. doi: 10.1016/j.mrfmmm.2013.04.009.", "ArticleIdList": ["10.1016/j.mrfmmm.2013.04.009", "PMC3909961", "23688353"]}, {"Citation": "Geenen J.J.J., Linn S.C., Beijnen J.H., Schellens J.H.M. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. Clin. Pharmacokinet. 2018;57:427\u2013437. doi: 10.1007/s40262-017-0587-4.", "ArticleIdList": ["10.1007/s40262-017-0587-4", "29063517"]}, {"Citation": "Singh D.D., Yadav D.K. TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy. Biomedicines. 2021;9:876. doi: 10.3390/biomedicines9080876.", "ArticleIdList": ["10.3390/biomedicines9080876", "PMC8389539", "34440080"]}, {"Citation": "Kalimutho M., Parsons K., Mittal D., Lopez J.A., Srihari S., Khanna K.K. Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends Pharmacol. Sci. 2015;36:822\u2013846. doi: 10.1016/j.tips.2015.08.009.", "ArticleIdList": ["10.1016/j.tips.2015.08.009", "26538316"]}, {"Citation": "Ueng S.H., Chen S.C., Chang Y.S., Hsueh S., Lin Y.C., Chien H.P., Lo Y.F., Shen S.C., Hsueh C. Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas. Int. J. Clin. Exp. Pathol. 2012;5:806\u2013813.", "ArticleIdList": ["PMC3466984", "23071863"]}, {"Citation": "Vitali F., Cohen L.D., Demartini A., Amato A., Eterno V., Zambelli A., Bellazzi R. A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast Cancer. PLoS ONE. 2016;11:e0162407. doi: 10.1371/journal.pone.0162407.", "ArticleIdList": ["10.1371/journal.pone.0162407", "PMC5025072", "27632168"]}, {"Citation": "Vundavilli H., Datta A., Sima C., Hua J., Lopes R., Bittner M. Bayesian Inference Identifies Combination Therapeutic Targets in Breast Cancer. IEEE Trans. Biomed. Eng. 2019;66:2684\u20132692. doi: 10.1109/TBME.2019.2894980.", "ArticleIdList": ["10.1109/TBME.2019.2894980", "30676941"]}, {"Citation": "Tada H., Shiho O., Kuroshima K., Koyama M., Tsukamoto K. An improved colorimetric assay for interleukin 2. J. Immunol. Methods. 1986;93:157\u2013165. doi: 10.1016/0022-1759(86)90183-3.", "ArticleIdList": ["10.1016/0022-1759(86)90183-3", "3490518"]}, {"Citation": "Qu Z., Lin Y., Mok D.K., Bian Q., Tai W.C., Chen S. Arnicolide D Inhibits Triple Negative Breast Cancer Cell Proliferation by Suppression of Akt/mTOR and STAT3 Signaling Pathways. Int. J. Med. Sci. 2020;17:1482\u20131490. doi: 10.7150/ijms.46925.", "ArticleIdList": ["10.7150/ijms.46925", "PMC7359397", "32669950"]}, {"Citation": "Chen G., Gong R., Shi X., Yang D., Zhang G., Lu A., Yue J., Bian Z. Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1. Oncotarget. 2016;7:50302\u201350314. doi: 10.18632/oncotarget.10367.", "ArticleIdList": ["10.18632/oncotarget.10367", "PMC5226584", "27385212"]}, {"Citation": "Qu Z., Lin Y., Mok D.K., Bian Q., Tai W.C., Chen S. Brevilin A, a Natural Sesquiterpene Lactone Inhibited the Growth of Triple-Negative Breast Cancer Cells via Akt/mTOR and STAT3 Signaling Pathways. OncoTargets Ther. 2020;13:5363\u20135373. doi: 10.2147/OTT.S256833.", "ArticleIdList": ["10.2147/OTT.S256833", "PMC7293987", "32606754"]}, {"Citation": "Saran U., Chandrasekaran B., Tyagi A., Shukla V., Singh A., Sharma A.K., Damodaran C. A small molecule inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth. Front. Pharmacol. 2023;14:1150774. doi: 10.3389/fphar.2023.1150774.", "ArticleIdList": ["10.3389/fphar.2023.1150774", "PMC9998682", "36909163"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "7", "Day": "12"}, {"Year": "2023", "Month": "8", "Day": "17"}, {"Year": "2023", "Month": "8", "Day": "17"}, {"Year": "2023", "Month": "12", "Day": "17", "Hour": "9", "Minute": "44"}, {"Year": "2023", "Month": "12", "Day": "9", "Hour": "10", "Minute": "43"}, {"Year": "2023", "Month": "12", "Day": "9", "Hour": "1", "Minute": "4"}, {"Year": "2023", "Month": "11", "Day": "22"}], "PublicationStatus": "epublish", "ArticleIdList": ["38067432", "PMC10707582", "10.3390/molecules28237701", "molecules28237701"]}}], "PubmedBookArticle": []}